Stimulants and the developing brain
- PMID: 15860370
- DOI: 10.1016/j.tips.2005.03.009
Stimulants and the developing brain
Abstract
For almost 70 years, children have received stimulants for the treatment of attention deficit hyperactivity disorder [ADHD (initially called hyperkinetic syndrome)], with little understanding of the long-term effects of these drugs on brain development. The maturation and refinement of the brain during childhood and adolescence, including the overproduction and selective elimination of synapses, is based on genetic programming and experience. The effects of stimulant drugs during different stages of this process have unique short-term, acute effects that also influence their long-term effects. Chronic, pre-pubertal exposure alters the expected developmental trajectory of brain structure and function and results in a different topography in adulthood. The timing of exposure (childhood versus adolescence), the age of examination after drug exposure (immediately or delayed into adulthood) and sex influence the observable effects. Preclinical studies of the effects of stimulant exposure provide increased understanding about the impact of stimulant drugs on brain development and provide insight into new treatment options for ADHD and other disorders of childhood.
Similar articles
-
Stimulant medications.J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):503-12. doi: 10.1097/00004583-199905000-00011. J Am Acad Child Adolesc Psychiatry. 1999. PMID: 10230181 Review.
-
Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.Expert Rev Neurother. 2006 Apr;6(4):551-61. doi: 10.1586/14737175.6.4.551. Expert Rev Neurother. 2006. PMID: 16623654 Review.
-
Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.Expert Rev Neurother. 2007 Apr;7(4):351-62. doi: 10.1586/14737175.7.4.351. Expert Rev Neurother. 2007. PMID: 17425490 Review.
-
Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.Child Care Health Dev. 2006 Sep;32(5):575-83. doi: 10.1111/j.1365-2214.2006.00631.x. Child Care Health Dev. 2006. PMID: 16919137
-
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder.J Psychopharmacol. 2006 Sep;20(5):602-10. doi: 10.1177/0269881106061710. Epub 2006 Feb 14. J Psychopharmacol. 2006. PMID: 16478756 Review.
Cited by
-
Levels of BDNF and NGF in adolescent rat hippocampus neonatally exposed to methamphetamine along with environmental alterations.Physiol Res. 2023 Dec 29;72(S5):S559-S571. doi: 10.33549/physiolres.935216. Physiol Res. 2023. PMID: 38165760 Free PMC article.
-
Exposure to early adversity: Points of cross-species translation that can lead to improved understanding of depression.Dev Psychopathol. 2015 May;27(2):477-91. doi: 10.1017/S0954579415000103. Dev Psychopathol. 2015. PMID: 25997766 Free PMC article. Review.
-
Methylphenidate disrupts cytoskeletal homeostasis and reduces membrane-associated lipid content in juvenile rat hippocampus.Metab Brain Dis. 2018 Jun;33(3):693-704. doi: 10.1007/s11011-017-0177-z. Epub 2017 Dec 29. Metab Brain Dis. 2018. PMID: 29288365
-
What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ).Eur Child Adolesc Psychiatry. 2013 Sep;22(9):533-42. doi: 10.1007/s00787-013-0393-y. Epub 2013 Mar 2. Eur Child Adolesc Psychiatry. 2013. PMID: 23455602
-
Methylphenidate Causes Behavioral Impairments and Neuron and Astrocyte Loss in the Hippocampus of Juvenile Rats.Mol Neurobiol. 2017 Aug;54(6):4201-4216. doi: 10.1007/s12035-016-9987-y. Epub 2016 Jun 21. Mol Neurobiol. 2017. PMID: 27324900
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical